Key facts
- Notable investors include Activate Global, Michigan Rise, Innovation Partnerships, University of Michigan, Canyon Oak Ventures — 20 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Intero Biosystems
- ·The full record, as it builds
Funding rounds
No funding rounds for Intero Biosystems are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Intero Biosystems
Developer of stem-cell-derived human organoid models designed for preclinical testing purposes. The company's platform features miniature organs that incorporate functioning neurons, blood vessels, muscle, and intestinal lining, enabling pharmaceutical researchers and biotechnology companies to conduct more reliable, human-relevant drug testing and development with improved consistency, scalability, and physiological accuracy, ultimately accelerating the path to better therapeutic outcomes.
- Sector
- Healthcare
- HQ
- MI
- Founded
- 2024
- Employees
- 6
- Website
- interobiosystems.com/
- Ownership
- Privately Held (backing)
Intero Biosystems doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Intero Biosystems shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Intero Biosystems in its N-PORT filings yet. We sweep new filings monthly.